The present invention relates to a method for producing embryonic stem cell-derived cardiomyocytes, cardiomyocytes produced by the method, a method for producing cardiomyocyte bodies from the cardiomyocytes, cardiomyocyte bodies produced by the method, a cellular therapeutic agent comprising the cardiomyocyte bodies as an active ingredient for the treatment of cardiac diseases, a method for treating cardiac diseases using the cellular therapeutic agent, and use of cardiomyocytes or cardiomyocyte bodies for the preparation of the cellular therapeutic agent. The method for producing cardiomyocytes of the present invention can be used to easily purify differentiated cardiomyocytes from embryonic stem cells. Further, the purified cardiomyocytes can be used to produce cardiomyocyte bodies, which can be used as a cellular therapeutic agent for treating cardiac diseases. Therefore, the cardiomyocyte bodies can be widely applied to the development of prophylactic or therapeutic agents for cardiac diseases.
